Prostatic Hyperplasia Clinical Trial
Official title:
Holmium Laser Enucleation of the Prostate Versus Monopolar Transurethral Resection of the Prostate in Management of Benign Prostatic Hyperplasia.
To compare the clinical outcome regarding safety and efficacy between Holmium laser enucleation of the prostate and transurethral resection of the prostate in management of benign prostatic hyperplasia.
Benign prostatic hyperplasia (BPH) affects 70% of men older than 70 years and is a
significant cause of morbidity in this population.
The symptoms of BPH include impaired physiological and functional well-being, which
interferes with daily living.
Lower urinary tract symptoms (LUTS) in elderly men are mainly related to an enlarged
prostate, the actual link between an enlarged prostate and the onset of symptoms are
multifactorial.
LUTS include both irritative symptoms in the form of urgency, frequency, nocturnal enuresis
and urge incontinence as well as obstructive symptoms comprise hesitancy, weak interrupted
stream of urine, incomplete voiding which eventually affect the quality of life (QoL), the
main goal of treatment is resolve these symptom.
Multiple surgical options are available for management of benign prostatic hyperplasia (BPH)
and its associated symptoms. Transurethral resection of the prostate (TURP) and open
prostatectomy remain the gold standard surgical management. However, considerable morbidities
are associated with both procedures and mainly related to the prostate size.
These complications may be either patient or surgically related. The patient's related
complications are cardiac arrhythmia, myocardial infarction, pulmonary embolism, exacerbation
of previous respiratory disease, deep venous thrombosis and death. The surgical related
complication includes bleeding, capsular perforation, urosepsis, incontinence, conversion to
open surgery, bladder neck stenosis, redo surgery and transurethral resection syndrome.
Clearly, a wide gap existed between simple medical therapy on one hand and TURP on the other
hand. This wide gap is coupled with the need for a less morbid alternative to TURP that led
to the emergence of various less invasive therapy among which Laser based minimally invasive
procedure.
Modern laser therapy for BPH has advantages over TURP including decreased blood loss and
minimal serum electrolyte changes resulting in fewer cardiovascular complications, decreased
catheter time, shorter hospital stay and the ability to treat patients on anticoagulation.
Because of these potential advantages, there has been a shift in practice patterns with laser
procedures accounting for 57% of surgical interventions for BPH, compared to traditional TURP
which accounted for only 39% of interventions in 2005.
Holmium laser enucleation of the prostate (HoLEP) is the most recent step in the evolution of
holmium laser prostatectomy. HoLEP is a safe and effective surgical procedure, which has
comparable results to transurethral resection of the prostate (TURP) and open prostatectomy,
with low morbidity and short hospital stay.
HoLEP is equally suitable for small, medium, and large prostate glands, with clinical
outcomes that are independent of prostate size, and recently it has been proposed as a new
gold standard for treatment of symptomatic benign prostatic hyperplasia (BPH). Currently, all
BPH guidelines recommend HoLEP as a surgical treatment of BPH.
For a procedure to be considered a gold standard, it must provide effective results, low
morbidity, and durable outcomes. HoLEP, as many of the new alternative treatments for
symptomatic BPH, has scanty data regarding its role in Egyptian population and if it can
replace TURP to be the gold standard.
To our best knowledge, no one estimated cost effectiveness between the two techniques in a
developing country.
Our study aimed to compare the efficacy, safety and cost effectiveness of HoLEP versus
monopolar TURP in management of benign prostatic hyperplasia in a developing country.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02578953 -
Bioequivalence Study of Dutasteride Capsules in Healthy Japanese Male Subjects
|
Phase 1 | |
| Terminated |
NCT02396420 -
Prostate Artery Embolization as a Treatment for Benign Prostatic Hyperplasia in Men With Prostates Larger Than 90 Grams
|
Phase 2 | |
| Terminated |
NCT04398966 -
Prostatic Artery Embolization vs Medication for Benign Prostatic Hyperplasia
|
N/A | |
| Not yet recruiting |
NCT06452927 -
EEP in Patients With Urodynamically Proven DU/DA
|
N/A | |
| Completed |
NCT02947958 -
Teleconsultation in Counter-reference Between Tertiary and Primary Care for Patients With Benign Prostatic Hyperplasia
|
N/A | |
| Completed |
NCT01937871 -
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)
|
Phase 3 | |
| Completed |
NCT00427882 -
Male Sexual Health Questionnaire (MSHQ) - Sexual Function Study
|
Phase 4 | |
| Completed |
NCT02244320 -
Observational Study in Patients With Functional Benign Prostatic Hyperplasia Symptoms Who Switched From Phytotherapy to ALNA® (Tamsulosin)
|
N/A | |
| Completed |
NCT01254071 -
A Study to Determine the Bioavailability of a Fixed Dose Combination Product of Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) Relative to Co-administration of the Individual Components in Healthy Male Subjects of North East Asian and Non-Asian Ancestry.
|
Phase 1 | |
| Recruiting |
NCT04108871 -
Whether Transperineal Prostate Biopsy Under Local-anaesthesia Using a Transperineal-access System is Non-inferior to Standard Transrectal Biopsy to Detect Prostate Cancer in Biopsy-naïve Men
|
N/A | |
| Recruiting |
NCT05686525 -
Clinical Trial on the Effectiveness of TUMT Compared to PAE in Reducing Severe LUTS in Men With BPH
|
N/A | |
| Completed |
NCT01957189 -
This Will be an Open-label, Three-period, Fixed-sequence Study to Evaluate the Drug-drug Interaction, Pharmacokinetics and Safety of Dutasteride and Tamsulosin When Administered Alone and In-combination in Chinese Healthy Male Volunteers. The Study Will Last Approximately Eleven Weeks. Blood Samples
|
Phase 1 | |
| Completed |
NCT00316732 -
Observational AVODART (Dutasteride) Study In Benign Prostatic Hyperplasia Subjects - OASIS
|
N/A | |
| Completed |
NCT02715401 -
PK and Safety of HCP1303 and Co-administration of HGP1201, HIP1402 Under Fed Condition in Healthy Male Volunteers
|
Phase 1 | |
| Recruiting |
NCT02278679 -
Digital Rectal Exam Proficiency Tool
|
N/A | |
| Completed |
NCT01482676 -
The Role of microRNAs in Organ Remodeling in Lower Urinary Tract Dysfunction
|
N/A | |
| Completed |
NCT01376258 -
Benefits of Adherence to 5-alpha Reductase Inhibitor Treatment in Men With Enlarged Prostate: An Assessment of Medicare and Medicaid Patients Using the MarketScan Database
|
N/A | |
| Completed |
NCT00822952 -
Prostate Mechanical Imager (PMI) Clinical Bridging Study
|
N/A | |
| Completed |
NCT00527605 -
Dutasteride 0.5mg For The Treatment Of Chinese Patients With Benign Prostatic Hyperplasia (BPH)
|
Phase 3 | |
| Terminated |
NCT00563485 -
Randomized Trial Comparing Terazosin 5 mg Daily and Doxazosin GITS 4 mg Daily for Trial Without Catheter in Acute Urinary Retention With Long Term Follow up
|
N/A |